Bronchogen: Respiratory Bioregulator
Last updated: March 2026
Bronchogen (Ala-Glu-Asp-Leu) is a Khavinson bioregulator tetrapeptide designed for respiratory tissue research. With a molecular weight of 446.45 g/mol, this small peptide crosses cellular membranes to interact with bronchial tissue at the molecular level.
🧪 Buy Bronchogen at Swiss Chems →AEDL
Weight
Lung Tissue
📋 On this page
What Is Bronchogen?
Bronchogen belongs to the Khavinson bioregulator family — short peptides that interact with DNA to modulate gene expression in specific tissues. Bronchogen targets bronchial and respiratory tissue, with proposed bronchodilating and anti-inflammatory properties.
Designed to interact specifically with bronchial epithelial cells and respiratory tissue. The AEDL sequence shows preferential binding to lung-tissue DNA regulatory regions.
Research suggests bronchodilating effects — relaxing airway smooth muscle to improve airflow. May modulate expression of genes controlling bronchial tone.
Anti-inflammatory properties in respiratory tissue models. May reduce inflammatory cytokine expression in bronchial cells, potentially relevant for respiratory conditions.
As a bioregulator, proposed to support cellular repair and regeneration in respiratory tissue by restoring peptide pools that decline with aging and damage.
What the Research Shows
Context: Bronchogen research is early-stage and limited. Data comes from in vitro cell models and the broader Khavinson bioregulator framework. No clinical trials in respiratory patients have been published. The evidence base is significantly thinner than for compounds like Epitalon.
Side Effects & Safety Profile
Study Citations
Self-Assessment
Who Researches Bronchogen?
This Research Is Commonly Explored By People Who...
- Are interested in peptide-based approaches to respiratory health
- Follow the Khavinson bioregulator research program
- Want to understand tissue-specific peptide interactions with lung cells
- Are exploring bioregulators as a class (often alongside Epitalon, Vilon, Testagen)
This Research May Not Be Relevant If...
- You want clinical trial data — none exists for Bronchogen
- You need proven respiratory treatments — see your doctor
- You want well-characterized mechanisms — data is very preliminary
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
Key Takeaways
- Tetrapeptide (AEDL) targeting respiratory tissue
- Part of established Khavinson bioregulator class
- Proposed bronchodilating and anti-inflammatory properties
- Small enough to cross cellular membranes (446 Da)
- No clinical trials in humans
- Very limited published research specific to Bronchogen
- Exact mechanism and efficacy not validated
- Not FDA approved — research only
- No long-term safety data
🔬 Verified Research Source
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports HighPeptides at no extra cost.
Research Supplies
Tools and supplies relevant to this research area.
As an Amazon Associate, HighPeptides earns from qualifying purchases.
Bronchogen is NOT FDA approved and is available only for research purposes. Evidence is very limited. This page is for educational purposes only. Not medical advice. Research Only